JP2022531408A5 - - Google Patents
Info
- Publication number
- JP2022531408A5 JP2022531408A5 JP2021565064A JP2021565064A JP2022531408A5 JP 2022531408 A5 JP2022531408 A5 JP 2022531408A5 JP 2021565064 A JP2021565064 A JP 2021565064A JP 2021565064 A JP2021565064 A JP 2021565064A JP 2022531408 A5 JP2022531408 A5 JP 2022531408A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- antibody
- galectin
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962841732P | 2019-05-01 | 2019-05-01 | |
| US62/841,732 | 2019-05-01 | ||
| PCT/US2020/031181 WO2020223702A1 (en) | 2019-05-01 | 2020-05-01 | Anti-galectin-9 antibodies and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022531408A JP2022531408A (ja) | 2022-07-06 |
| JP2022531408A5 true JP2022531408A5 (enExample) | 2023-05-11 |
| JP7581238B2 JP7581238B2 (ja) | 2024-11-12 |
Family
ID=73029403
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021565064A Active JP7581238B2 (ja) | 2019-05-01 | 2020-05-01 | 抗ガレクチン９抗体およびその使用 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US20220178930A1 (enExample) |
| EP (1) | EP3962954A4 (enExample) |
| JP (1) | JP7581238B2 (enExample) |
| CN (2) | CN119033928A (enExample) |
| AU (1) | AU2020266677A1 (enExample) |
| CA (1) | CA3138863A1 (enExample) |
| SG (1) | SG11202112112UA (enExample) |
| WO (2) | WO2020223702A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019084553A1 (en) | 2017-10-27 | 2019-05-02 | New York University | ANTI-GALECTIN-9 ANTIBODIES AND USES THEREOF |
| CN119033928A (zh) * | 2019-05-01 | 2024-11-29 | 纽约大学 | 抗半乳糖凝集素-9抗体及其用途 |
| AU2021205143A1 (en) | 2020-01-07 | 2022-07-28 | Hifibio, Inc. | Anti-Galectin-9 antibody and uses thereof |
| US20240109968A1 (en) * | 2020-11-20 | 2024-04-04 | New York University | Anti-galectin-9 antibodies and therapeutic uses thereof |
| EP4329808A4 (en) * | 2021-04-30 | 2025-03-12 | PureTech LYT, Inc. | Combination of anti-galectin-9 antibodies and chemotherapeutics for use in cancer therapy |
| AU2022266821A1 (en) * | 2021-04-30 | 2023-11-09 | Puretech Lyt, Inc. | Anti-galectin-9 antibodies and therapeutic uses thereof |
| WO2023056461A1 (en) * | 2021-10-01 | 2023-04-06 | Puretech Lyt, Inc. | Anti-galectin-9 antibodies and therapeutic uses thereof |
| KR20250029919A (ko) * | 2022-06-29 | 2025-03-05 | 퓨어테크 엘와이티, 아이엔씨. | 갈렉틴-9를 억제하는 항체를 사용한 혈액학적 악성종양의 치료 |
| CN120585880B (zh) * | 2025-08-07 | 2025-12-09 | 四川大学华西医院 | 一种用于预防和/或治疗前列腺癌的联合用药物，其用途及药物组合物 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5021309B2 (ja) * | 2003-10-16 | 2012-09-05 | ステファン ジョン ラルフ | 免疫調節性組成物およびその使用方法 |
| BRPI0518994A2 (pt) * | 2004-12-31 | 2008-12-02 | Biogen Idec Inc | anticorpos ou polipeptÍdeos que se ligam a br3, seus usos e formulaÇÕes lÍquidas |
| WO2007064919A2 (en) * | 2005-12-02 | 2007-06-07 | Genentech, Inc. | Binding polypeptides with restricted diversity sequences |
| CA2710398A1 (en) * | 2008-01-18 | 2009-10-15 | Genentech, Inc. | Methods and compositions for targeting polyubiquitin |
| MX2011000655A (es) * | 2008-07-18 | 2011-03-21 | Oragenics Inc | Composiciones para la deteccion y tratamiento de cancer colorrectal. |
| AU2011326564A1 (en) * | 2010-11-10 | 2013-05-09 | Genentech, Inc. | Methods and compositions for neural disease immunotherapy |
| KR20130103587A (ko) * | 2010-12-09 | 2013-09-23 | 가르파마 컴퍼니 리미티드 | 갈렉틴 9를 분비하는 세포, 그 제조 방법 및 그 용도 |
| FR3021970B1 (fr) * | 2014-06-06 | 2018-01-26 | Universite Sciences Technologies Lille | Anticorps dirige contre la galectine 9 et inhibiteur de l'activite suppressive des lymphocytes t regulateurs |
| AU2015343425A1 (en) * | 2014-11-04 | 2017-05-25 | Dana-Farber Cancer Institute, Inc. | Anti-galectin antibody biomarkers predictive of anti-immune checkpoint and anti-angiogenesis responses |
| WO2017044308A1 (en) * | 2015-09-10 | 2017-03-16 | Albert Einstein College Of Medicine, Inc. | Synthetic antibodies to bax and uses thereof |
| WO2017202962A1 (en) * | 2016-05-24 | 2017-11-30 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of non small cell lung cancer (nsclc) that coexists with chronic obstructive pulmonary disease (copd) |
| CN111050791A (zh) * | 2017-06-27 | 2020-04-21 | 诺华股份有限公司 | 用于抗tim-3抗体的给药方案及其用途 |
| US12030940B2 (en) * | 2017-08-17 | 2024-07-09 | Nektar Therapeutics | Immunotherapeutic tumor treatment method |
| WO2019084553A1 (en) * | 2017-10-27 | 2019-05-02 | New York University | ANTI-GALECTIN-9 ANTIBODIES AND USES THEREOF |
| CA3134942A1 (en) * | 2019-03-25 | 2020-10-01 | New York University | Anti-galectin-9 antibodies and uses thereof |
| CN119033928A (zh) * | 2019-05-01 | 2024-11-29 | 纽约大学 | 抗半乳糖凝集素-9抗体及其用途 |
| WO2021022256A1 (en) * | 2019-08-01 | 2021-02-04 | New York University | Combined cancer therapy of anti-galectin-9 antibodies and chemotherapeutics |
| CN116782934A (zh) * | 2020-10-26 | 2023-09-19 | 纯技术Lyt股份有限公司 | 抗半乳糖凝集素9抗体及其在治疗眼部黑素瘤中的用途 |
| US20240109968A1 (en) * | 2020-11-20 | 2024-04-04 | New York University | Anti-galectin-9 antibodies and therapeutic uses thereof |
| WO2022109302A1 (en) * | 2020-11-20 | 2022-05-27 | New York University | Anti-galectin-9 antibodies and therapeutic uses thereof |
| EP4329808A4 (en) * | 2021-04-30 | 2025-03-12 | PureTech LYT, Inc. | Combination of anti-galectin-9 antibodies and chemotherapeutics for use in cancer therapy |
| AU2022266821A1 (en) * | 2021-04-30 | 2023-11-09 | Puretech Lyt, Inc. | Anti-galectin-9 antibodies and therapeutic uses thereof |
-
2020
- 2020-05-01 CN CN202411238025.5A patent/CN119033928A/zh active Pending
- 2020-05-01 CN CN202080047488.7A patent/CN114026126B/zh active Active
- 2020-05-01 WO PCT/US2020/031181 patent/WO2020223702A1/en not_active Ceased
- 2020-05-01 US US17/607,879 patent/US20220178930A1/en not_active Abandoned
- 2020-05-01 AU AU2020266677A patent/AU2020266677A1/en active Pending
- 2020-05-01 WO PCT/US2020/031184 patent/WO2020223704A1/en not_active Ceased
- 2020-05-01 US US17/607,878 patent/US20220185896A1/en not_active Abandoned
- 2020-05-01 JP JP2021565064A patent/JP7581238B2/ja active Active
- 2020-05-01 CA CA3138863A patent/CA3138863A1/en active Pending
- 2020-05-01 EP EP20798582.1A patent/EP3962954A4/en active Pending
- 2020-05-01 SG SG11202112112UA patent/SG11202112112UA/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023130496A (ja) | 癌治療のための併用療法 | |
| JP2020508317A5 (enExample) | ||
| JP2018522850A5 (enExample) | ||
| JP2014533279A5 (enExample) | ||
| JP2016530323A5 (enExample) | ||
| KR20170007750A (ko) | Ｈｐｖ-음성 암의 치료를 위한 ｐｄｌ-1의 길항제 및 ｐｄ-1의 길항제 | |
| JP2023551559A5 (enExample) | ||
| JP2020529469A5 (enExample) | ||
| O'Donnell et al. | Combined modality radioimmunotherapy for human prostate cancer xenografts with taxanes and 90yttrium‐DOTA‐peptide‐ChL6 | |
| EP3380521A1 (en) | Combination therapy for cancer | |
| JP2025060639A (ja) | Ｐｄ－１／ｐｄ－ｌ１シグナル伝達阻害剤に不応答性のがんの処置方法および医薬 | |
| JP2015528802A5 (enExample) | ||
| JP2020507596A5 (enExample) | ||
| JP2023539625A5 (enExample) | ||
| JP2024540435A5 (enExample) | ||
| TWI870592B (zh) | 使用免疫檢查點抑制劑抗體治療癌症之方法和組合 | |
| JP2023551980A5 (enExample) | ||
| CN111166878B (zh) | 靶向肿瘤抗原的抗体与iNKT细胞的组合的制备方法与用途 | |
| CN115957321A (zh) | 一种抗her2抗体在制备治疗癌症的药物中的用途 | |
| JP2024519450A5 (enExample) | ||
| AU2022318734A1 (en) | Methods for treating acute myeloid leukemia with anti-ilt3 antibodies | |
| WO2021213523A1 (zh) | 抗pd-1抗体和抗ctla-4抗体的组合在预防或治疗癌症中的用途 | |
| JP2022534494A5 (enExample) | ||
| WO2017176565A1 (en) | Combinations of an anti-b7-h1 antibody and a cxcr4 peptide antagonist for treating a solid tumor | |
| JP2025526402A5 (enExample) |